Andrew Bradbury (Birmingham, UK) reported that a new randomised controlled trial, BASIL 2, has been launched because there is an “urgent need” to undertake pragmatic, scientifically robust and publically-funded randomised controlled trials of endovascular interventions in patients with severe limb ischaemia.
The final, two-year data from the RENOVA trial that compared the use of the Flair stent-graft (Bard) to the use of percutaneous transluminal angioplasty for treatment of arteriovenous graft stenosis showed that stent grafts proved as safe as angioplasty and more effective.
Para controlar el colesterol y mantenerlo a raya es fundamental seguir unos hábitos de vida saludables que incluyan una alimentación variada y equilibrada y ejercicio físico diario. Juana Morillas, experta en nutrición consultada por el Instituto Flora, afirma que es fundamental cuidarnos durante todo el año. “Debemos intentar tomar 3 frutas y 2 raciones de hortalizas al día, incluir alimentos integrales, priorizar las carnes blancas y los pescados frente las carnes rojas, y el aceite de oliva, las margarinas y los frutos secos frente la mantequilla” asegura la Dra. Morillas. En el caso de las personas con hipercolesterolemia, es aconsejable combinar estos hábitos saludables con alimentos enriquecidos con esteroles y estanoles vegetales.
Un grupo de investigadores del IDIAP Jordi Gol estudia si hay relación entre el índice tobillo-brazo (la medida del índice tobillo-brazo es un elemento de detección de la enfermedad arterial periférica) y la incidencia de eventos cardiovasculares en población mayor de 49 años en España.
Lombard Medical Technologies announced that Lombard Medical has filed a registration statement on Form F-1 with the US Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the offering have not yet been determined.
The Charing Cross Symposium (5—8 April 2014, Grand Hall Olympia, London, UK) will feature three full days of peripheral arterial disease management topics this year. The programme dedicated to lower limb intervention will start with the peripheral arterial day in the Main Programme on Saturday and continue with the LINC @ CX peripheral intervention programme on Sunday and the CX ilegx Collaboration Day on Monday.
Results from six-month data of the PES BTK-70 study have shown 86.2% primary patency in the treatment of short focal lesions in below-the-knee arteries with the self-expanding paclitaxel-eluting Stentys stent. Nearly 90% freedom from target lesion revascularisation was achieved and there was over 98% limb salvage rate.
Thomas Nolte, vascular surgeon and director of Vascular Center, Herz und Gefäßzentrum, Bad Bevensen, Germany, recently commented on the importance of sealing in the endovascular treatment of abdominal aortic aneurysm.
Spectranetics announced that the EXCITE ISR trial achieved the statistical endpoints of the adjunct analysis. According to a company press release, the trial evaluates laser atherectomy plus percutaneous transluminal angioplasty compared with percutaneous transluminal angioplasty alone for the treatment of in-stent restenosis (ISR) in patients suffering from peripheral artery disease.
W L Gore & Associates (Gore) has announced in a press release that the results of the REVISE clinical study showed that the Gore Viabahn endoprosthesis with Heparin Bioactive Surface is superior to percutaneous transluminal angioplasty - the current standard of care for treating stenoses or thrombotic occlusions.
Recognising that new technologies and techniques are revolutionising how venous disorders are treated, in 2014, for the first time, the Charing Cross Symposium (5–8 April, London, UK) will host three days of venous activities. This year, the CX Office-based Vein Practice Course has been extended over two full days—Sunday and Monday—and will be followed by a day of venous talks in the Venous Consensus Update session of the Main Programme on Tuesday.
A study that compared the durability of thoracic endovascular aortic repair (TEVAR) in two similar clinical trials, one that used early-generation and another that used later-generation stent grafts, found a significantly lower freedom from reintervention rate for patients who received the newer stent grafts.
Vascutek has announced the return to market of the Anaconda bifurcate body stent graft system for patients with abdominal aortic aneurysms. The system was voluntarily recalled in October 2013 following the identification of a potential issue with the release wire in the delivery system.
Cardiovascular Systems has announced that it has received US Food and Drug Administration (FDA) clearance of its new Diamondback 360 60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD).
A recent budget impact model of endovascular interventions in the USA and Germany found not only that drug-eluting balloons are a cost-effective therapy, but also that at current reimbursement rates, payer economics are in conflict with provider economics.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos